Overview
Nippon India Pharma Fund Direct Growth
Nippon India Mutual Fund
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Investments in Nippon India Pharma Fund Direct Growth are subject to market risks. Please read the offer document carefully before investing to understand the potential market risks and rewards.
Latest NAV
₹ 547.4118
Fund Size (AUM)
₹8080.97 Cr
Risk
Very High (Risk rating: 6/10)
Minimum Investment
Lumpsum: ₹ 5000
SIP: ₹100
Launch Date
31-Dec-2012
Expense Ratio
0.91%
Exit Load
Exit load of 1% if redeemed within 1 month.
Benchmark
BSE Healthcare Total Return Index
Standard Deviation
15.85
History
Performance & Ratios
1-Year SIP Return
-4.72%
3-Year SIP Return
21.64%
5-Year SIP Return
19.44%
Mean Return
1.39%
Alpha
0.51
Beta
0.9
Sharpe Ratio
0.82
Sortino Ratio
1.28
Information Ratio
-0.24
Returns
| 1Y | 3Y | 5Y | All Time | |
|---|---|---|---|---|
| Fund Returns | 18.76% | 19.69% | 23.31% | 17.73% |
| Category Average | 19.46% | 17.92% | 21.75% | N/A |
| Rank Within Category | 12 | 7 | 6 | N/A |
Holdings (36)
| Company | Sector | Instrument | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | Equity | 13.43% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 9.28% |
| Lupin Ltd. | Healthcare | Equity | 7.27% |
| Cipla Ltd. | Healthcare | Equity | 5.71% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 5.31% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 5.19% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | Equity | 3.61% |
| Vijaya Diagnostic Centre Ltd. | Healthcare | Equity | 3.53% |
| Abbott India Ltd. | Healthcare | Equity | 3.46% |
| Medplus Health Services Ltd. | Healthcare | Equity | 3.41% |
Holdings Analysis
Peer Comparison
SIP, STP & SWP Details
Systematic Investment Plan (SIP):
Frequency: Monthly
Min Amount: ₹ 100
Multiplier: 1
Systematic Transfer Plan (STP):
Frequency: MONTHLY
Dates: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
Min Amount: ₹ 1000
Min Installments: 2
Systematic Withdrawal Plan (SWP):
Frequency: MONTHLY
Dates: 1, 8, 15, 22
Min Amount: ₹ 500
Min Installments: 1
AMC Details
Asset Management Company
Nippon India Mutual Fund
Reliance Mutual Fund started their mutual fund on 30/06/1995 and its managing total assets of ₹2,32,169 Cr. Its ranked at 3 as per total assets at end of 30th Sep 2017. Nippon India Mutual Fund employs robust strategies to manage market risks, but investments remain subject to market risks. Please read the fund’s documentation for detailed risk management policies.
Reliance Mutual Fund is a part of Reliance Anil Dhirubhai Ambani (ADA) Group and it is one of the largest growing asset management companies in India. It has an asset under management of Rs 239,145.
Reliance Mutual Fund is present across 160 cities across the country. The main motto of the asset management company is to launch products that are not only innovative, but also conducive for investors. They believe in increasing their value to investors.
RMF provides a host of mutual funds across various categories, be it equity, debt and hybrid. The schemes have a well-managed portfolio and it has pioneered to become one of the most trusted asset management companies in India.
Reliance Mutual Fund has been sponsored by Reliance Capital Limited and Nippon Life Insurance Company.
Launch Date
1995-06-30T00:00:00.010Z
Total AUM
₹ 560218.54 Cr
Address
4th Floor, Tower A, Peninsula Business Park,Ganapatrao Kadam Marg, Lower Parel (W), Mumbai 400013
Phone
None
Website
Sub Type
Contra
Sub Type Info
Contra funds follow Contrarian strategy which means investing in stocks in contrast to the prevailing sentiment. Minimum investment in equity is 65%.
Tax Impact
Returns are taxed at 20%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 12.5% on returns of Rs 1.25 lakh+ in a financial year.
Stamp Duty
0.005% (from July 1st, 2020)
Fund Manager Details
Compare with Another Fund
Nippon India Pharma Fund Direct Growth
Nippon India Mutual Fund
You May Be Interested In
Nippon India Flexi Cap Fund Direct Growth
Flexi Cap
Bandhan Nifty 50 Index Fund Direct Plan Growth
Large Cap
HSBC Small Cap Fund Direct Growth
Small Cap
Kotak ELSS Tax Saver Fund Direct Growth
ELSS
Nippon India Nifty Next 50 Junior BeES FoF Direct Growth
Large Cap
Axis Multicap Fund Direct Growth
Multi Cap
Motilal Oswal Nifty 500 Index Fund Direct Growth
Flexi Cap
Canara Robeco ELSS Tax Saver Direct Growth
ELSS
Kotak Flexicap Fund Direct Growth
Flexi Cap
HDFC NIFTY Next 50 Index Fund Direct Growth
Large Cap
Explore More Mutual Funds
Debt Mutual Funds - Best Debt Fund Options
Discover top debt mutual funds for stable returns. Filter by NAV, fund size, and AMC to find the best debt funds for you.
Hybrid Mutual Funds - Top Hybrid Funds
Find top hybrid mutual funds for balanced growth. Filter by NAV, fund size, and risk to choose the best hybrid funds.
Commodities Mutual Funds
Explore commodities mutual funds for diversification. Filter by NAV and fund size to find the best commodity funds.
ELSS Mutual Funds - Top Tax-Saving Funds
Discover top ELSS mutual funds for tax savings and growth. Filter by NAV, fund size, and AMC to find the best ELSS funds.
Frequently Asked Questions
How is the overall rating calculated?
The overall rating for Nippon India Pharma Fund Direct Growth is an aggregate score based on performance metrics (returns over 1, 3, and 5 years), risk-adjusted returns (Sharpe and Sortino ratios), and consistency relative to its category. Ratings are on a scale of 1 to 5, with 5 being the highest.
What are the top stocks of Nippon India Pharma Fund Direct Growth?
The top stocks held by Nippon India Pharma Fund Direct Growth include Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Lupin Ltd..
Which industries does Nippon India Pharma Fund Direct Growth invest in?
Nippon India Pharma Fund Direct Growth primarily invests in the following industries: Healthcare.
Who is the fund manager of Nippon India Pharma Fund Direct Growth?
The fund manager of Nippon India Pharma Fund Direct Growth is Sailesh Raj Bhan.
How many years has the fund manager been managing Nippon India Pharma Fund Direct Growth?
Sailesh Raj Bhan: Calculating...
What is the minimum investment for Nippon India Pharma Fund Direct Growth?
The minimum investment for Nippon India Pharma Fund Direct Growth is ₹5000 for lumpsum investments and ₹100 for SIPs.
What are the average 1-year returns for Nippon India Pharma Fund Direct Growth?
Calculating...
What are the average 3-year returns for Nippon India Pharma Fund Direct Growth?
Calculating...
What is the expense ratio of Nippon India Pharma Fund Direct Growth, and how does it compare to its category?
The expense ratio of Nippon India Pharma Fund Direct Growth is 0.91%. No category comparison data is available.